We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Effect of respiratory muscle endurance training on respiratory sensations, respiratory control and exercise performance: a 15-year experience.
Respiratory Physiology & Neurobiology 2008 March 21
Respiratory muscle endurance training (RMET) can improve respiratory muscle endurance as well as cycling and swimming endurance. Whether these improvements are caused by reduced perception of adverse respiratory sensations and/or a change in ventilatory output remains unclear. We re-analysed nine (five randomized controlled) RMET studies performed in our laboratory. One hundred and thirty-five healthy subjects completed either RMET [i.e. an average of 12.4+/-4.9h (median 10; range 10-25) of normocapnic hyperpnoea at 60-85% of maximal voluntary ventilation achieved during 27+/-11 sessions (median 20; range 20-50) of 29+/-4min (median 30; range 15-30) duration over 6.5+/-4.2 weeks (median 4; range 4-15), n=90] or no RMET (CON, n=45). Before and after RMET/CON, respiratory ( approximately 70% MVV) and cycling (70-85% maximal power) endurance were tested. RMET increased both respiratory and cycling endurance, reduced perception of breathlessness and respiratory exertion during volitional and exercise-induced hyperpnoea, and slightly increased ventilation at identical workloads. Decreased respiratory sensations did not correlate with improved cycling endurance. Changes in ventilation correlated with changes in cycling endurance in both groups. We conclude that reduced adverse respiratory sensations after RMET are unlikely to cause the improvements in cycling endurance, that the level of ventilation seems to affect cycling endurance and that additional factors must contribute to the improvements in cycling endurance after RMET.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app